MagnetisMM-8: Study Of Elranatamab (PF-06863135) Monotherapy in Chinese Participants With Refractory Multiple Myeloma
Status:
Recruiting
Trial end date:
2025-01-29
Target enrollment:
Participant gender:
Summary
Study C1071008 includes 2 parts. The objective of Phase 1b part is to establish the safety
profile in order to confirm the monotherapy RP2D in Chinese participants. The Phase 2 part is
a single stage design to evaluate the efficacy and safety in Chinese participants.
Elranatamab is a bispecific antibody: binding of Elranatamab to CD3-expressing T-cells and
BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.